- Home
- COYA
as 02-21-2025 4:00pm EST
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.
| Founded: | 2020 | Country: | United States |
| Employees: | N/A | City: | HOUSTON |
| Market Cap: | 98.5M | IPO Year: | 2022 |
| Target Price: | $16.25 | AVG Volume (30 days): | 92.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.77 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.75 - $10.69 | Next Earning Date: | 03-18-2025 |
| Revenue: | $9,554,315 | Revenue Growth: | N/A |
| Revenue Growth (this year): | -38.81% | Revenue Growth (next year): | 56.22% |
Latest Coya Therapeutics Inc. News
COYA Breaking Stock News: Dive into COYA Ticker-Specific Updates for Smart Investing
Benzinga
16 days ago
Coya Therapeutics' Alzheimer's Candidate Shows Improved Inflammatory Blood Markers Following Monthly Dosing
Business Wire
16 days ago
Coya Therapeutics Reports Statistically Significant Improvement of Inflammatory Blood Markers in Patients with Alzheimer’s Disease Following Monthly Dosing with Low-Dose IL-2, Further Supporting Clinical Development
Business Wire
18 days ago
Coya Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Pharma Voice
a month ago
An ALS treatment wave is approaching, and this biotech CEO is ready to surf
Business Wire
a month ago
Coya Therapeutics Announces Pipeline Expansion - COYA 303: COYA 301 in Combination with GLP-1 Receptor Agonist for the Treatment of Inflammatory Diseases
Benzinga
a month ago
EXCLUSIVE: Coya Therapeutics Expands Its Pipeline With Combo Therapy For Inflammatory Diseases
Business Wire
2 months ago
Coya Therapeutics Provides Enrollment Update of the Investigator-Initiated Phase 1 Study of Low Dose Interleukin-2 (LD IL-2) + CTLA4-Ig Fusion Protein in Patients with Frontotemporal Dementia (FTD)
Business Wire
3 months ago
Coya Therapeutics to Participate in a Fireside Chat at the 7th Annual Evercore HealthCONx Conference
Compare COYA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "COYA Coya Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.